Analyst Tycho Peterson of Jefferies reiterated a Buy rating on Labcorp Holdings, with a price target of $300.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tycho Peterson has given his Buy rating due to a combination of factors that highlight Labcorp Holdings’ strong financial performance and promising outlook. The company reported a 1% top-line beat, driven by improvements in its Biopharma Lab Services and Diagnostics Laboratories segments. The Biopharma Lab Services segment showed a 6% revenue beat with significant organic growth, while the Diagnostics Laboratories segment maintained solid performance with a 4.5% organic growth.
Furthermore, Labcorp’s earnings per share exceeded expectations, and the company raised its full-year revenue and earnings guidance, reflecting favorable foreign exchange impacts. The esoteric diagnostics segment is outpacing the market, and the company is strategically positioning itself in oncology. Despite potential policy headwinds, Labcorp’s ability to manage these challenges and its strong free cash flow conversion support a positive outlook, justifying the Buy rating.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year.